New Agilent expansion will ‘more than double’ nucleic acid API manufacture
pharmafile | August 10, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Agilent, expansion, manufacturing, oligonucleotide
Agilent Technologies is set to expand its pharmaceutical manufacturing operations with a 20-acre facility in Weld County, Colorado.
The facility is anticipated to increase manufacturing capacity for nucleic acid active pharmaceutical ingredients by more than 100%, adding between 150 and 200 new, permanent high-salary jobs.
“The products manufactured at this site will be used by our customers to improve the lives of patients suffering from a variety of diseases,” said Skip Thune, general manager of Agilent’s Nucleic Acids Solutions Division. “At Agilent, we are committed to meeting the ever-increasing needs of our customers for oligonucleotides.”
Oligonucleotides (short DNA and RNA molecules) are believed to have the potential to treat various forms of cancer, diabetes, muscular dystrophy and other disorders.
Matt Fellows
Related Content
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
AbbVie invests $223m in Singapore manufacturing site
AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing …